High-risk men 'should get prostate cancer checks'

Some men over 40 would benefit from annual blood tests, researchers say.
Source: BBC News | Health | UK Edition - Category: Consumer Health News Source Type: news

Related Links:

Publication date: Available online 10 November 2019Source: European UrologyAuthor(s): Amar U. Kishan, Fang-I Chu, Christopher R. King, Wendy Seiferheld, Daniel E. Spratt, Phuoc Tran, Xiaoyan Wang, Stephanie E. Pugh, Kiri A. Sandler, Michel Bolla, Philippe Maingon, Theo De Reijke, Nicholas G. Nickols, Matthew Rettig, Alexandra Drakaki, Sandy T. Liu, Robert E. Reiter, Albert J. Chang, Felix Y. Feng, Dipti SajedAbstractBackgroundThe importance of local failure (LF) after treatment of high-grade prostate cancer (PCa) with definitive radiotherapy (RT) remains unknown.ObjectiveTo evaluate the clinical implications of LF after de...
Source: European Urology - Category: Urology & Nephrology Source Type: research
Abstract Due to some inconsistencies in the figures provided by the first author that have come to light, and after a thorough investigation we would like to retract our paper: "Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer. By: Zalazar F, De Luca P, Gardner K, Figg WD, Meiss R, Spallanzani RG, Vallecorsa P, Elguero B, Cotignola J, Vazquez E, De Siervi A. Curr. Pharm. Biotechnol., 2015, 16(6), 553-63. Submission of a manuscript to the respective journals implies that all authors have read and agreed to the content of the Copyright Letter or the Terms and C...
Source: Current Pharmaceutical Biotechnology - Category: Biotechnology Authors: Tags: Curr Pharm Biotechnol Source Type: research
PROSTATE cancer symptoms usually don ’t show until the cancer has grown large enough, but with it being the most common cancer in men in the UK, it’s important to recognise the signs when they develop. Five symptoms may affect a man when he pees.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Publication date: Available online 9 November 2019Source: Genes &DiseasesAuthor(s): Ruixin Wang, Xiaoqi LiuAbstractProstate cancer is (PCa) the second leading cause of cancer death in males in the United State, with 174,650 new cases and 31,620 deaths estimated in 2019. It has been documented that epigenetic deregulation such as histone modification and DNA methylation contributes to PCa initiation and progression. EZH2 (enhancer of zeste homolog 2), the catalytic subunit of the Polycomb Repressive Complex (PRC2) responsible for H3K27me3 and gene repression, has been identified as a promising target in PCa. In addition...
Source: Genes and Diseases - Category: Genetics & Stem Cells Source Type: research
ConclusionsBaseline MRI before CBx during AS results in 50% fewer AS failures and less grade progression over 2 yr. The center where MRI and targeted biopsy is performed may influence AS failure rates.Patient summaryThe ASIST trial randomized 273 men on active surveillance with low-grade prostate cancer diagnosed within the last year to systematic biopsy or magnetic resonance imaging (MRI) with systematic and targeted biopsy. The initial report showed little benefit from targeted biopsy. However, after 2 yr of follow-up we found that baseline MRI before confirmatory biopsy resulted in 50% fewer failures of surveillance...
Source: European Urology - Category: Urology & Nephrology Source Type: research
ConclusionThe comparison of the cumulative incidence of SREs identified in routinely collected hospital data, based on a specific coding definition in patients diagnosed with different prostate cancer stage, supports their validity as a clinically important marker of cancer progression.
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
CONCLUSION: Our study demonstrated no clear association between the levels of serum OC and CTX and bisphosphonate-related osteonecrosis of the jaw (BRONJ). To date, there is no clinically useful biomarker for the prediction of jaw osteonecrosis. More studies are needed using different bone turnover markers in order to identify patients at risk for BRONJ. PMID: 31697256 [PubMed - in process]
Source: Archivos Espanoles de Urologia - Category: Urology & Nephrology Tags: Arch Esp Urol Source Type: research
CONCLUSIONS: Incidental prostate cancer had a higher prevalence than previously expected in our cohort (24.4%), but it had no impact in overall survival of patients not even in those with a significant prostate cancer. No biochemical recurrence was reported during the study. PMID: 31697251 [PubMed - in process]
Source: Archivos Espanoles de Urologia - Category: Urology & Nephrology Tags: Arch Esp Urol Source Type: research
ConclusionCombined HDR-B/EBRT for the treatment of clinically localized prostate cancer provides superb clinical outcomes with excellent 5-year bRFS, dMFS, OS, and late GI/GU toxicity rates.
Source: Journal of Radiation Oncology - Category: Cancer & Oncology Source Type: research
To assess the risk of biochemical recurrence (BCR) in small low-grade prostate tumours following radical prostatectomy (RP), which are defined as clinically insignificant based on the existing criteria developed by Stamey and Epstein.
Source: Urology - Category: Urology & Nephrology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Health | Prostate Cancer